Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Joe Biden wants diabetes drugs that aid weight loss and treat obesity, such as Wegovy, to fall under Medicare and Medicaid.

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

In a cohort study of 232 236 patients, patients with an eGFR of <15 mL/min/1.73 m 2 (not on dialysis) had a 2.5 times greater risk of in-hospital mortality after acute ischaemic stroke compared with ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.

A new study published in the journal Jama estimated that more than 137 million American adults are eligible for medications ...

Factors beyond carbohydrates have a substantial influence on blood glucose levels meaning current automated insulin delivery ...

highlighting the potential for therapeutic interventions aimed at optimizing both gut and kidney function. The interplay between the gut and kidney has garnered significant attention in recent years, ...